Why immune rebalancing is the heart of cell therapy
Quick answer
There are over 100 autoimmune diseases, arising when the Th1/Th2 T-cell balance breaks and immunity attacks the body's own tissue. EHL Bio explains that stem cells help restore Th1/Th2 equilibrium, giving them potential in this disease group, and that they normalise both under- and over-active immunity. That is why cell therapy is being trialled across conditions from atopic dermatitis to rheumatoid arthritis.
Th1 and Th2 are helper T-cell subsets pulling in different directions: Th1 handles intracellular pathogens and inflammation, Th2 drives antibody production and allergic responses. When one dominates, allergy or autoimmunity follows.
MSCs modulate immunity through several routes: expanding regulatory T cells, dampening antigen-presenting cell activity and secreting anti-inflammatory mediators — nudging the system toward balance rather than blanket suppression like steroids.
The caution: many of these diseases have no cure and some carry life-threatening complications, so swapping the immunosuppressants that currently control the disease for cell therapy is a risk not worth taking.
Ask for evidence specific to your own disease: data in one condition do not transfer to another. Evidence in graft-versus-host disease is entirely different from SLE or multiple sclerosis.
Research exists but it is not standard care; SLE patients should remain under continuous rheumatology care.
The concept is rebalancing rather than suppression, but infection monitoring after treatment is still necessary.
It depends on the disease and protocol — some give two doses, others repeat cycles based on response.
Disease-specific markers such as ESR/CRP, validated severity indices and measurable clinical symptoms.
Last updated: 2026-08-28 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categoriesRelated topics: Joints & immunity